Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Application, Type, and Geography - Forecast and Analysis 2023-2027

Vascular Endothelial Growth Factor Inhibitors Market Forecast 2023-2027

The Vascular Endothelial Growth Factor Inhibitors Market is estimated to increase by USD 10.40 billion at a CAGR of 7.76% between 2022 and 2027. 

The market tackles urgent medical demands linked with vascular disorders, notably age-related macular degeneration (AMD), prevalent among the elderly. Driven by biotechnology, it prioritizes drug development and clinical trials to combat conditions associated with diabetes. With a focus on innovative therapies, the sector aims to alleviate the burden of AMD and similar ailments. By leveraging advancements in drug research and development, it seeks to enhance treatment efficacy and patient outcomes. This strategic approach underscores the market's commitment to addressing critical healthcare needs and improving the quality of life for individuals affected by vascular disorders and related complications.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

The VEGF Inhibitors market witnesses robust growth driven by increasing patient epidemiology and advancements in pipeline analysis. These inhibitors play a pivotal role in curbing the formation of new blood vessels crucial in diseases like cancer, particularly ovarian and cervical cancer. The prevalence of diseases like colon and rectum cancer, bronchus cancer, and age-related macular degeneration highlights the importance of understanding patient epidemiologySupported by a stringent regulatory framework, pharmaceutical companies and biopharma firms are actively engaged in eye care, focusing on conditions like macular edema and retinal vein occlusion, prevalent in AMD (Age-related macular degeneration). The patent cliff has spurred the development of biosimilar drugs targeting angiogenesis. Notable inhibitors like Avastin are central to combating diabetic retinopathy and other ophthalmic conditions, driving significant market acquisition in lung and vascular therapies.

Market Segmentation 

The market is a critical segment in healthcare, addressing conditions like hypertension, stroke, and heart attack, among others. Innovations from companies like Allergan Aesthetics and advancements in neuroscience research are driving progress in treating ailments associated with VEGF, including cancers like leukemia and renal pelvis cancer. Approved by the FDA, medications like Eylea offer hope by targeting VEGF to combat tumor growth and mitigate complications like bleeding and reversible posterior leukoencephalopathy syndrome. Understanding the strengths and weaknesses of pharmaceutical firms is vital in shaping the future of VEGF inhibitor therapies.

By Application

The market share growth of the oncology segment will be significant during the forecast period. VEGF inhibitors have a major application in the oncology segment, as almost all these drugs are approved for oncology indications. VEGF Inhibitor Market Analysis inhibitors that are commonly used in the oncology segment include bevacizumab (Avastin), aflibercept (Zaltrap), and ramucirumab (Cyramza). These drugs can be administered as monotherapy or in combination with chemotherapy, radiation therapy, or other cancer treatments.

Get a glance at the market contribution of various segments Request a PDF Sample

The oncology segment was valued at USD 11.75 billion in 2017 and continued to grow until 2021. The oncology segment of the VEGF inhibitors market is growing rapidly due to the increasing incidence of cancer, the availability of new drugs, and the high demand for effective cancer treatments, which, in turn, contribute to the growth of the global VEGF inhibitors market during the forecast period.

Market Dynamics

The market witnesses robust growth driven by increasing patient epidemiology and advancements in pipeline analysis. These inhibitors play a pivotal role in curbing the formation of new blood vessels crucial in diseases like cancer, particularly ovarian and cervical cancer. Supported by a stringent regulatory framework, pharmaceutical companies and biopharma firms are actively engaged in eye care, focusing on conditions like macular edema and retinal vein occlusion, prevalent in AMD (Age-related macular degeneration). The patent cliff has spurred the development of biosimilar drugs targeting angiogenesis. Notable inhibitors like Avastin are central to combating diabetic retinopathy and other ophthalmic conditions, driving significant market acquisition in lung and vascular therapies. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The strategic alliances formed regarding collaboration and licensing are notably driving market growth. These alliances help to co-develop and commercialize VEGF inhibitors worldwide. Co-development agreements enable the use of technical expertise from both companies, which in turn would help them promote and support each other to develop and market novel drugs. Such agreements also ensure the in-flow of adequate funds for the companies involved and reduce liability costs incurred by individual companies in case of failures, thereby attracting more venture investments.

For instance, Amgen Inc. (Amgen) and Allergan plc. formed a collaboration to develop and commercialize four oncology antibody biosimilar medicines, including MVASI. Such strategic alliances and collaborations help companies in covering larger geographical areas and speed up the development of new drugs with significant investments. The products are co-developed and marketed through alliances, which enables companies to gain higher returns on investment. Hence, such strategic alliances are expected to propel the growth of the VEGF inhibitors market during the forecast period.

Significant Market Trends

The growing popularity of combination therapies is the key trend in the market. The global VEGF inhibitors market has a substantial number of drugs treating cancer and eye disorders. However, as per the research by pharmaceutical companies, some metastatic cancer does not respond to a monotherapy drug. Drugs treating cancer are most effective when given in combination. In combination therapy, drugs working on different mechanisms act on the site, thereby decreasing the likelihood that resistant cancer cells will develop.

When drugs with different effects are combined, each drug can be used at its optimal dose without intolerable side effects. Thus, there has been a rise in the use of a combination of chemotherapies to treat cancer as well as ophthalmic conditions, which will have a positive impact on the VEGF inhibitors market during the forecast period.

Major Market Challenge

Preference for gene therapy is the major market challenges impeding market growth, particularly in the Cancer Treatment Market and Ophthalmic Drugs Market. With recent research developments in oncology and ophthalmology, it has been discovered that several carcinomas and eye disorders are caused due to abnormal gene mutations, impacting the Macular Degeneration Treatment Market and Diabetic Retinopathy Treatment Market. These gene mutations occur from the damage to genes in a cell during a person's lifespan, highlighting the challenges in the Anti-Angiogenic therapy and Anti-VEGF therapeutics market.

Gene therapy is the latest revolution in the treatment landscape for therapy areas, primarily oncology and ophthalmology, shaping the VEGF Inhibitor Market Outlook. Gene therapy can broadly be explained as the introduction of genetic material into cells to fix the abnormalities of gene or protein production, influencing VEGF Inhibitor Market Dynamics. The minimum side effects and remissive nature of this therapy make this a popular treatment option, especially for oncology indications such as glioma and pancreatic cancer, along with ophthalmic indications such as AMD. Thus, increasing preference for gene therapy will hamper the growth of the global VEGF inhibitors market during the forecast period, highlighting VEGF Inhibitor Market Opportunities and Challenges.

Key Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Who are the Major Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AstraZeneca Plc - The company offers, manufactures, and sells a wide range of pharmaceutical and medical products. The company offers vascular endothelial growth factor inhibitors that are used directly into the myocardium of patients undergoing elective coronary artery bypass surgery, under the brand name of AZD8601.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• Bristol Myers Squibb Co.
• Clovis Oncology
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• LG Chem Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Regional Analysis

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The growth of the market in this region is primarily driven by the sales of approved VEGF inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC. According to the National Program of Cancer Registries (NPCR), carried out by the Centers for Disease Control and Prevention (CDC), more than 28.5 million invasive cancer cases have been diagnosed in the last two decades. It further explains that more than 1 million new invasive cancer cases are reported every year. 

Furthermore, the market in this region is driven by the increasing awareness programs conducted by companies and organizations. Such programs encourage cancer patients to undergo treatment. For instance, the International Association for the Study of Lung Cancer, a non-profit organization, focuses on increasing awareness about the disease globally

Market Analyst Overview

The market is a vital component of the anti-VEGF drugs market and the broader angiogenesis inhibitors market, playing a crucial role in cancer treatment, particularly in ophthalmic drugs for conditions like macular degeneration and diabetic retinopathy, reflecting market growth analysis. These anti-angiogenic therapies target abnormal blood vessel growth, inhibiting the progression of diseases, and contributing to market research and growth. VEGF inhibitor drugs and VEGF inhibitor therapy are pivotal in managing these conditions, offering hope to patients worldwide, as outlined in the market research report.

 

Additionally, the market is at the forefront of cancer treatment, particularly in combating conditions like ovarian cancer, prostate cancer, and breast cancer formation. Leading biopharmaceutical companies such as Molecular Partners are actively engaged in research activities to develop innovative oncology candidates like Osimertinib. FDA-approved drugs like Tecentriq and Cometriq offer promising outcomes in immunology and hematologic oncology. Despite notable strengths and weaknesses in production capacities, the market faces challenges such as gastrointestinal perforations and impaired wound healing. However, with ongoing product launches and pricing analyses, the future scope for VEGF inhibitors like Eylea and Brolucizumab remains promising in addressing critical medical needs and advancing cancer therapy.

Healthcare spending aims to improve patient awareness and education while managing treatment costs and addressing safety concerns. Despite regulatory obstacles and the need for authorizations, the market strives for standardization in therapy regimens to ensure effectiveness in patient groups. Long-term safety concerns prompt exploration into alternative therapies amid economic insecurity. Market analysis reveals dynamic VEGF inhibitor market trends and opportunities for growth, emphasizing market growth and forecasting, despite challenges such as high costs and accessibility issues. As research continues to advance, the inhibitor market remains poised for expansion, driven by ongoing developments in treatment modalities and increased awareness of their benefits, highlighting market forecasting and the outlook for the VEGF Inhibitor Market.

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Application Outlook
  • Oncology
  • Ophthalmology

• Type Outlook
  • VEGF-A inhibitor
  • VEGF-B inhibitor
  • VEGF-C inhibitor
  • VEGF-D inhibitor

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina
    • Rest of the Middle East & Africa

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Scope
Report Coverage	Details
Page number	166
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 7.76%
Market growth 2023-2027	USD 10.40 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	6.96
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 44%
Key countries	US, Canada, UK, Germany, and Japan
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology, Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Viatris Inc., and Xbrane Biopharma AB
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the VEGF inhibitor market size and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this report to meet your requirements. Get in touch